Skip to content

Author

Paul N. Knöbl

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Teclistamab for the treatment of autoantibody-mediated coagulation disorders.

BACKGROUND Teclistamab is a bispecific monoclonal antibody that targets B cell maturation antigen (BCMA) on plasma cells and other B lineage cells and CD3 on T cells, thereby redirecting cytotoxic T cells to eliminate BCMA-expressing antibody-producing cells. Autoantibody-mediated coagulation disorders are often driven...

Johannes Thaler, K. Gleixner, L. Eischer et al. · 0 citations
Open access Sep 2026

Recombinant ADAMTS13 in congenital thrombotic thrombocytopenic purpura: final analysis from a randomized phase 3 trial.

Recombinant ADAMTS13 (rADAMTS13) was approved for prophylactic or on-demand ADAMTS13 replacement therapy for congenital thrombotic thrombocytopenic purpura (TTP) based on data from a preplanned interim analysis of a phase 3, open-label, crossover trial (NCT03393975). Here, we report results from the final analysis with...

M. Scully, M. Matsumoto, S. Cataland et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.